A Critical Assessment of Boron Neutron Capture Therapy: An Overview

  title={A Critical Assessment of Boron Neutron Capture Therapy: An Overview},
  author={Rolf F. Barth},
  journal={Journal of Neuro-Oncology},
  • R. Barth
  • Published 2004
  • Medicine
  • Journal of Neuro-Oncology
Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with neutrons of the appropriate energy to produce high-energy alpha particles and recoiling lithium-7 nuclei. BNCT has been used clinically to treat patients with high-grade gliomas, and a much smaller number with primary and metastatic melanoma. The purpose of this special issue of the Journal of Neuro-Oncology is to provide a critical and realistic assessment of various aspects of… 
3 Citations
Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor–Positive Glioma Using Boronated Cetuximab
These data convincingly show the therapeutic efficacy of molecular targeting of EGFR using a boronated mAb either alone or in combination with BPA and provide a platform for the future development of combinations of high and low molecular weight delivery agents for BNCT of brain tumors.


Boron neutron capture therapy of brain tumors: an emerging therapeutic modality.
The present review covers the biological and radiobiological considerations on which BNCT is based, boron-containing low- and high-molecular weight delivery agents, neutron sources, clinical studies, and future areas of research.
Boron Neutron Capture Therapy for Glioblastoma Multiforme: Clinical Studies in Sweden
A boron neutron capture therapy (BNCT) facility has been constructed at Studsvik, Sweden and, presently, a protocol for BNCT treatment of glioblastoma patients who have not received any therapy other than surgery is involved.
Assessment of the Results from the Phase I/II Boron Neutron Capture Therapy Trials at the Brookhaven National Laboratory from a Clinician's Point of View
  • A. Diaz
  • Medicine
    Journal of Neuro-Oncology
  • 2004
It is the ratio of the 10B concentration in tumor cells to that in the normal brain cells and the blood that will largely determine the therapeutic gain of BNCT.
Boron Neutron Capture Therapy of Brain Tumors: Clinical Trials at the Finnish Facility Using Boronophenylalanine
BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients, and effectiveness comparisons with conventional photon radiation are difficult due to patient selection and confounding factors.
Ligand Liposomes and Boron Neutron Capture Therapy
Boron neutron capture therapy (BNCT) has been used both experimentally and clinically for the treatment of gliomas and melanomas, with varying results, but it is uncertain whether enough boron is taken up by micro-invasive tumor cells.
Rat Brain Tumor Models to Assess the Efficacy of Boron Neutron Capture Therapy: A Critical Evaluation
These studies demonstrated that BNCT either cured or significantly prolonged the survival of tumor-bearing rats and provided proof of principle for the use of high molecular weight, receptor targeting-boron delivery agents.
Common Challenges and Problems in Clinical Trials of Boron Neutron Capture Therapy of Brain Tumors
The BNCT community needs to standardize each aspect of the design, implementation, and reporting of clinical trials so that the data can be used meaningfully.
The Use of Positron Emission Tomography to Develop Boron Neutron Capture Therapy Treatment Plans for Metastatic Malignant Melanoma
PET imaging with 18F-BPA can be used to identify potential tumors that may be amenable to boron neutron capture therapy (BNCT) and to improve treatment plans prior to BNCT.
Fission Reactor Neutron Sources for Neutron Capture Therapy – A Critical Review
It should be possible to design and construct new low power reactors specifically for NCT, which meet all requirements for routine therapy and which are based on proven and highly safe reactor technology.
Pharamacokinetic Modeling for Boronophenylalanine-fructose Mediated Neutron Capture Therapy: 10B Concentration Predictions and Dosimetric Consequences
The ability of this model to predict, in advance, the average blood 10B concentration during brief irradiations was simulated in a retrospective analysis of the pharmacokinetic data from these patients, and error in delivered dose for a given single irradiation field resulting from error in predicted blood 10 B concentration was limited to less than 10%.